CN118356470A - Traditional Chinese medicine composition for treating coronary heart disease and angina pectoris with syndrome of turbid phlegm and blood stasis and preparation method thereof - Google Patents
Traditional Chinese medicine composition for treating coronary heart disease and angina pectoris with syndrome of turbid phlegm and blood stasis and preparation method thereof Download PDFInfo
- Publication number
- CN118356470A CN118356470A CN202410584320.XA CN202410584320A CN118356470A CN 118356470 A CN118356470 A CN 118356470A CN 202410584320 A CN202410584320 A CN 202410584320A CN 118356470 A CN118356470 A CN 118356470A
- Authority
- CN
- China
- Prior art keywords
- parts
- chinese medicine
- traditional chinese
- medicine composition
- radix
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000003814 drug Substances 0.000 title claims abstract description 100
- 239000000203 mixture Substances 0.000 title claims abstract description 64
- 239000008280 blood Substances 0.000 title claims abstract description 56
- 210000004369 blood Anatomy 0.000 title claims abstract description 56
- 208000029078 coronary artery disease Diseases 0.000 title claims abstract description 49
- 206010002383 Angina Pectoris Diseases 0.000 title claims abstract description 42
- 206010062717 Increased upper airway secretion Diseases 0.000 title claims abstract description 40
- 208000026435 phlegm Diseases 0.000 title claims abstract description 40
- 238000002360 preparation method Methods 0.000 title claims abstract description 24
- 208000011580 syndromic disease Diseases 0.000 title claims description 12
- 239000002994 raw material Substances 0.000 claims abstract description 32
- 244000020518 Carthamus tinctorius Species 0.000 claims abstract description 25
- 235000003255 Carthamus tinctorius Nutrition 0.000 claims abstract description 25
- 241000218176 Corydalis Species 0.000 claims abstract description 25
- 241001522129 Pinellia Species 0.000 claims abstract description 25
- 241000304531 Allium macrostemon Species 0.000 claims abstract description 24
- 244000183685 Citrus aurantium Species 0.000 claims abstract description 24
- 235000007716 Citrus aurantium Nutrition 0.000 claims abstract description 24
- 241000112528 Ligusticum striatum Species 0.000 claims abstract description 21
- 240000006023 Trichosanthes kirilowii Species 0.000 claims abstract description 21
- 235000009818 Trichosanthes kirilowii Nutrition 0.000 claims abstract description 21
- 235000009917 Crataegus X brevipes Nutrition 0.000 claims abstract description 19
- 235000013204 Crataegus X haemacarpa Nutrition 0.000 claims abstract description 19
- 235000009685 Crataegus X maligna Nutrition 0.000 claims abstract description 19
- 235000009444 Crataegus X rubrocarnea Nutrition 0.000 claims abstract description 19
- 235000009486 Crataegus bullatus Nutrition 0.000 claims abstract description 19
- 235000017181 Crataegus chrysocarpa Nutrition 0.000 claims abstract description 19
- 235000009682 Crataegus limnophila Nutrition 0.000 claims abstract description 19
- 240000000171 Crataegus monogyna Species 0.000 claims abstract description 19
- 235000004423 Crataegus monogyna Nutrition 0.000 claims abstract description 19
- 235000002313 Crataegus paludosa Nutrition 0.000 claims abstract description 19
- 235000009840 Crataegus x incaedua Nutrition 0.000 claims abstract description 19
- 239000004863 Frankincense Substances 0.000 claims abstract description 19
- 235000003717 Boswellia sacra Nutrition 0.000 claims abstract description 18
- 235000012035 Boswellia serrata Nutrition 0.000 claims abstract description 18
- 240000007551 Boswellia serrata Species 0.000 claims abstract description 18
- 244000077995 Coix lacryma jobi Species 0.000 claims abstract description 14
- 235000006200 Glycyrrhiza glabra Nutrition 0.000 claims abstract description 14
- 244000303040 Glycyrrhiza glabra Species 0.000 claims abstract description 14
- 235000006040 Prunus persica var persica Nutrition 0.000 claims abstract description 14
- 244000144730 Amygdalus persica Species 0.000 claims abstract description 13
- 244000197580 Poria cocos Species 0.000 claims abstract description 13
- 235000008599 Poria cocos Nutrition 0.000 claims abstract description 13
- LPLVUJXQOOQHMX-QWBHMCJMSA-N glycyrrhizinic acid Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@H](O[C@@H]1O[C@@H]1C([C@H]2[C@]([C@@H]3[C@@]([C@@]4(CC[C@@]5(C)CC[C@@](C)(C[C@H]5C4=CC3=O)C(O)=O)C)(C)CC2)(C)CC1)(C)C)C(O)=O)[C@@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O LPLVUJXQOOQHMX-QWBHMCJMSA-N 0.000 claims abstract description 12
- 235000011477 liquorice Nutrition 0.000 claims abstract description 12
- 229940100688 oral solution Drugs 0.000 claims description 35
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 25
- 240000007164 Salvia officinalis Species 0.000 claims description 20
- 235000005412 red sage Nutrition 0.000 claims description 19
- 238000001914 filtration Methods 0.000 claims description 15
- 238000000034 method Methods 0.000 claims description 14
- 238000009835 boiling Methods 0.000 claims description 13
- 238000002156 mixing Methods 0.000 claims description 13
- 235000006484 Paeonia officinalis Nutrition 0.000 claims description 11
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 claims description 8
- 229930006000 Sucrose Natural products 0.000 claims description 8
- 239000005720 sucrose Substances 0.000 claims description 8
- 238000002791 soaking Methods 0.000 claims description 7
- 238000004140 cleaning Methods 0.000 claims description 6
- 239000000463 material Substances 0.000 claims description 6
- 238000007865 diluting Methods 0.000 claims description 5
- 238000011049 filling Methods 0.000 claims description 5
- 230000001954 sterilising effect Effects 0.000 claims description 5
- 239000006228 supernatant Substances 0.000 claims description 5
- 238000005303 weighing Methods 0.000 claims description 5
- 235000013399 edible fruits Nutrition 0.000 claims description 4
- 235000008326 Trichosanthes anguina Nutrition 0.000 claims description 3
- 244000078912 Trichosanthes cucumerina Species 0.000 claims description 3
- 239000002775 capsule Substances 0.000 claims description 3
- 239000000839 emulsion Substances 0.000 claims description 3
- 239000008187 granular material Substances 0.000 claims description 3
- 239000006187 pill Substances 0.000 claims description 3
- 239000000725 suspension Substances 0.000 claims description 3
- 239000003826 tablet Substances 0.000 claims description 3
- 244000163122 Curcuma domestica Species 0.000 claims description 2
- 235000003392 Curcuma domestica Nutrition 0.000 claims description 2
- 241000212322 Levisticum officinale Species 0.000 claims description 2
- 241000244365 Ligusticum sinense Species 0.000 claims description 2
- 244000046146 Pueraria lobata Species 0.000 claims description 2
- 235000010575 Pueraria lobata Nutrition 0.000 claims description 2
- 235000003373 curcuma longa Nutrition 0.000 claims description 2
- 239000001645 levisticum officinale Substances 0.000 claims description 2
- 235000013976 turmeric Nutrition 0.000 claims description 2
- 244000170916 Paeonia officinalis Species 0.000 claims 2
- 230000000694 effects Effects 0.000 abstract description 38
- 208000024891 symptom Diseases 0.000 abstract description 26
- 230000006872 improvement Effects 0.000 abstract description 4
- 230000008901 benefit Effects 0.000 abstract description 3
- 230000007012 clinical effect Effects 0.000 abstract description 3
- 208000002193 Pain Diseases 0.000 description 35
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 15
- 230000001737 promoting effect Effects 0.000 description 14
- 210000000952 spleen Anatomy 0.000 description 13
- 206010008479 Chest Pain Diseases 0.000 description 11
- 241001106477 Paeoniaceae Species 0.000 description 9
- 230000003213 activating effect Effects 0.000 description 9
- 210000000038 chest Anatomy 0.000 description 8
- 229940079593 drug Drugs 0.000 description 8
- 210000002216 heart Anatomy 0.000 description 8
- 210000004072 lung Anatomy 0.000 description 8
- 210000002784 stomach Anatomy 0.000 description 8
- 201000000736 Amenorrhea Diseases 0.000 description 7
- 206010001928 Amenorrhoea Diseases 0.000 description 7
- 206010012735 Diarrhoea Diseases 0.000 description 7
- 231100000540 amenorrhea Toxicity 0.000 description 7
- 239000000706 filtrate Substances 0.000 description 7
- 210000004185 liver Anatomy 0.000 description 7
- 208000005171 Dysmenorrhea Diseases 0.000 description 6
- 208000004998 Abdominal Pain Diseases 0.000 description 5
- 206010007247 Carbuncle Diseases 0.000 description 5
- 206010013935 Dysmenorrhoea Diseases 0.000 description 5
- 206010019233 Headaches Diseases 0.000 description 5
- 230000017531 blood circulation Effects 0.000 description 5
- 239000000796 flavoring agent Substances 0.000 description 5
- 235000019634 flavors Nutrition 0.000 description 5
- 231100000869 headache Toxicity 0.000 description 5
- 208000014674 injury Diseases 0.000 description 5
- 238000012986 modification Methods 0.000 description 5
- 230000004048 modification Effects 0.000 description 5
- 239000000047 product Substances 0.000 description 5
- 210000000582 semen Anatomy 0.000 description 5
- 206010011224 Cough Diseases 0.000 description 4
- 230000009286 beneficial effect Effects 0.000 description 4
- 235000009508 confectionery Nutrition 0.000 description 4
- 208000002173 dizziness Diseases 0.000 description 4
- 235000013305 food Nutrition 0.000 description 4
- 230000008961 swelling Effects 0.000 description 4
- 230000035922 thirst Effects 0.000 description 4
- 230000008736 traumatic injury Effects 0.000 description 4
- 210000002700 urine Anatomy 0.000 description 4
- 206010010774 Constipation Diseases 0.000 description 3
- 206010037660 Pyrexia Diseases 0.000 description 3
- 208000005392 Spasm Diseases 0.000 description 3
- 206010047700 Vomiting Diseases 0.000 description 3
- 206010000891 acute myocardial infarction Diseases 0.000 description 3
- 208000006673 asthma Diseases 0.000 description 3
- 235000019658 bitter taste Nutrition 0.000 description 3
- 230000004087 circulation Effects 0.000 description 3
- 238000003745 diagnosis Methods 0.000 description 3
- 230000004064 dysfunction Effects 0.000 description 3
- 238000000605 extraction Methods 0.000 description 3
- 230000002496 gastric effect Effects 0.000 description 3
- 230000001717 pathogenic effect Effects 0.000 description 3
- 235000019633 pungent taste Nutrition 0.000 description 3
- 230000001105 regulatory effect Effects 0.000 description 3
- 238000007619 statistical method Methods 0.000 description 3
- 235000019640 taste Nutrition 0.000 description 3
- 210000002435 tendon Anatomy 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- 238000009210 therapy by ultrasound Methods 0.000 description 3
- 208000006820 Arthralgia Diseases 0.000 description 2
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 2
- 206010014080 Ecchymosis Diseases 0.000 description 2
- 208000034507 Haematemesis Diseases 0.000 description 2
- 235000017443 Hedysarum boreale Nutrition 0.000 description 2
- 235000007858 Hedysarum occidentale Nutrition 0.000 description 2
- 206010023126 Jaundice Diseases 0.000 description 2
- 206010028813 Nausea Diseases 0.000 description 2
- 244000131316 Panax pseudoginseng Species 0.000 description 2
- 241001619461 Poria <basidiomycete fungus> Species 0.000 description 2
- RYMZZMVNJRMUDD-UHFFFAOYSA-N SJ000286063 Natural products C12C(OC(=O)C(C)(C)CC)CC(C)C=C2C=CC(C)C1CCC1CC(O)CC(=O)O1 RYMZZMVNJRMUDD-UHFFFAOYSA-N 0.000 description 2
- 241000913745 Spatholobus Species 0.000 description 2
- 206010041956 Stasis syndrome Diseases 0.000 description 2
- 206010042674 Swelling Diseases 0.000 description 2
- AIGAZQPHXLWMOJ-UHFFFAOYSA-N Tanshinone I Chemical compound C1=CC2=C(C)C=CC=C2C(C(=O)C2=O)=C1C1=C2C(C)=CO1 AIGAZQPHXLWMOJ-UHFFFAOYSA-N 0.000 description 2
- 210000001015 abdomen Anatomy 0.000 description 2
- 206010000059 abdominal discomfort Diseases 0.000 description 2
- 229960001138 acetylsalicylic acid Drugs 0.000 description 2
- 208000022531 anorexia Diseases 0.000 description 2
- 208000005634 blind loop syndrome Diseases 0.000 description 2
- 230000036772 blood pressure Effects 0.000 description 2
- 230000001914 calming effect Effects 0.000 description 2
- 239000011248 coating agent Substances 0.000 description 2
- 238000000576 coating method Methods 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 238000001816 cooling Methods 0.000 description 2
- 238000002586 coronary angiography Methods 0.000 description 2
- 206010061428 decreased appetite Diseases 0.000 description 2
- 230000007547 defect Effects 0.000 description 2
- 208000001780 epistaxis Diseases 0.000 description 2
- 210000003414 extremity Anatomy 0.000 description 2
- 239000001947 glycyrrhiza glabra rhizome/root Substances 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- MOYKHGMNXAOIAT-JGWLITMVSA-N isosorbide dinitrate Chemical compound [O-][N+](=O)O[C@H]1CO[C@@H]2[C@H](O[N+](=O)[O-])CO[C@@H]21 MOYKHGMNXAOIAT-JGWLITMVSA-N 0.000 description 2
- 229960000201 isosorbide dinitrate Drugs 0.000 description 2
- 230000005906 menstruation Effects 0.000 description 2
- 230000004060 metabolic process Effects 0.000 description 2
- 208000010125 myocardial infarction Diseases 0.000 description 2
- 230000008693 nausea Effects 0.000 description 2
- 230000000144 pharmacologic effect Effects 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 230000009863 secondary prevention Effects 0.000 description 2
- 238000007873 sieving Methods 0.000 description 2
- RYMZZMVNJRMUDD-HGQWONQESA-N simvastatin Chemical compound C([C@H]1[C@@H](C)C=CC2=C[C@H](C)C[C@@H]([C@H]12)OC(=O)C(C)(C)CC)C[C@@H]1C[C@@H](O)CC(=O)O1 RYMZZMVNJRMUDD-HGQWONQESA-N 0.000 description 2
- 229960002855 simvastatin Drugs 0.000 description 2
- 208000010110 spontaneous platelet aggregation Diseases 0.000 description 2
- 235000019605 sweet taste sensations Nutrition 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 231100000331 toxic Toxicity 0.000 description 2
- 230000002588 toxic effect Effects 0.000 description 2
- 229940126680 traditional chinese medicines Drugs 0.000 description 2
- 210000001835 viscera Anatomy 0.000 description 2
- 238000003809 water extraction Methods 0.000 description 2
- XUCIJNAGGSZNQT-JHSLDZJXSA-N (R)-amygdalin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@H](O[C@@H](C#N)C=2C=CC=CC=2)O1 XUCIJNAGGSZNQT-JHSLDZJXSA-N 0.000 description 1
- HVCOBJNICQPDBP-UHFFFAOYSA-N 3-[3-[3,5-dihydroxy-6-methyl-4-(3,4,5-trihydroxy-6-methyloxan-2-yl)oxyoxan-2-yl]oxydecanoyloxy]decanoic acid;hydrate Chemical compound O.OC1C(OC(CC(=O)OC(CCCCCCC)CC(O)=O)CCCCCCC)OC(C)C(O)C1OC1C(O)C(O)C(O)C(C)O1 HVCOBJNICQPDBP-UHFFFAOYSA-N 0.000 description 1
- 206010000060 Abdominal distension Diseases 0.000 description 1
- 206010067484 Adverse reaction Diseases 0.000 description 1
- 208000007848 Alcoholism Diseases 0.000 description 1
- 206010003011 Appendicitis Diseases 0.000 description 1
- 206010003497 Asphyxia Diseases 0.000 description 1
- 206010003658 Atrial Fibrillation Diseases 0.000 description 1
- 206010003662 Atrial flutter Diseases 0.000 description 1
- 206010003671 Atrioventricular Block Diseases 0.000 description 1
- 241000717739 Boswellia sacra Species 0.000 description 1
- 206010006298 Breast pain Diseases 0.000 description 1
- 206010006578 Bundle-Branch Block Diseases 0.000 description 1
- 206010007882 Cellulitis Diseases 0.000 description 1
- 206010008190 Cerebrovascular accident Diseases 0.000 description 1
- 241000675108 Citrus tangerina Species 0.000 description 1
- 241000756943 Codonopsis Species 0.000 description 1
- 206010051625 Conjunctival hyperaemia Diseases 0.000 description 1
- 206010010726 Conjunctival oedema Diseases 0.000 description 1
- 201000000057 Coronary Stenosis Diseases 0.000 description 1
- 244000286838 Eclipta prostrata Species 0.000 description 1
- 206010016952 Food poisoning Diseases 0.000 description 1
- 208000019331 Foodborne disease Diseases 0.000 description 1
- 229930186217 Glycolipid Natural products 0.000 description 1
- 206010019468 Hemiplegia Diseases 0.000 description 1
- 208000032843 Hemorrhage Diseases 0.000 description 1
- 206010019909 Hernia Diseases 0.000 description 1
- 208000031226 Hyperlipidaemia Diseases 0.000 description 1
- 206010021143 Hypoxia Diseases 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 241000830535 Ligustrum lucidum Species 0.000 description 1
- 208000006662 Mastodynia Diseases 0.000 description 1
- 201000005505 Measles Diseases 0.000 description 1
- 208000019255 Menstrual disease Diseases 0.000 description 1
- 208000037093 Menstruation Disturbances Diseases 0.000 description 1
- 206010027339 Menstruation irregular Diseases 0.000 description 1
- 206010030113 Oedema Diseases 0.000 description 1
- 244000236658 Paeonia lactiflora Species 0.000 description 1
- 235000008598 Paeonia lactiflora Nutrition 0.000 description 1
- 206010033557 Palpitations Diseases 0.000 description 1
- 235000003181 Panax pseudoginseng Nutrition 0.000 description 1
- 235000005035 Panax pseudoginseng ssp. pseudoginseng Nutrition 0.000 description 1
- 235000003140 Panax quinquefolius Nutrition 0.000 description 1
- 229920000175 Pistacia lentiscus Polymers 0.000 description 1
- 208000004880 Polyuria Diseases 0.000 description 1
- 208000012287 Prolapse Diseases 0.000 description 1
- 240000005809 Prunus persica Species 0.000 description 1
- 244000086363 Pterocarpus indicus Species 0.000 description 1
- 235000009984 Pterocarpus indicus Nutrition 0.000 description 1
- 240000001341 Reynoutria japonica Species 0.000 description 1
- 235000018167 Reynoutria japonica Nutrition 0.000 description 1
- 244000042430 Rhodiola rosea Species 0.000 description 1
- 235000003713 Rhodiola rosea Nutrition 0.000 description 1
- 206010039424 Salivary hypersecretion Diseases 0.000 description 1
- 235000017276 Salvia Nutrition 0.000 description 1
- 206010041591 Spinal osteoarthritis Diseases 0.000 description 1
- 208000007718 Stable Angina Diseases 0.000 description 1
- 208000006011 Stroke Diseases 0.000 description 1
- 238000000692 Student's t-test Methods 0.000 description 1
- 208000033809 Suppuration Diseases 0.000 description 1
- 229930183118 Tanshinone Natural products 0.000 description 1
- 206010070863 Toxicity to various agents Diseases 0.000 description 1
- 208000003443 Unconsciousness Diseases 0.000 description 1
- 208000007814 Unstable Angina Diseases 0.000 description 1
- 206010046788 Uterine haemorrhage Diseases 0.000 description 1
- 206010047601 Vitamin B1 deficiency Diseases 0.000 description 1
- 208000000260 Warts Diseases 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 206010000269 abscess Diseases 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000006838 adverse reaction Effects 0.000 description 1
- 201000007930 alcohol dependence Diseases 0.000 description 1
- 230000001476 alcoholic effect Effects 0.000 description 1
- 229930013930 alkaloid Natural products 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 229940089837 amygdalin Drugs 0.000 description 1
- YZLOSXFCSIDECK-UHFFFAOYSA-N amygdalin Natural products OCC1OC(OCC2OC(O)C(O)C(O)C2O)C(O)C(O)C1OC(C#N)c3ccccc3 YZLOSXFCSIDECK-UHFFFAOYSA-N 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 239000006286 aqueous extract Substances 0.000 description 1
- 206010003119 arrhythmia Diseases 0.000 description 1
- 230000006793 arrhythmia Effects 0.000 description 1
- 229940107666 astragalus root Drugs 0.000 description 1
- 208000002894 beriberi Diseases 0.000 description 1
- 210000000941 bile Anatomy 0.000 description 1
- 230000000740 bleeding effect Effects 0.000 description 1
- 230000036770 blood supply Effects 0.000 description 1
- 239000006227 byproduct Substances 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 230000002612 cardiopulmonary effect Effects 0.000 description 1
- 208000036319 cervical spondylosis Diseases 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 229940126678 chinese medicines Drugs 0.000 description 1
- 238000003759 clinical diagnosis Methods 0.000 description 1
- 238000007374 clinical diagnostic method Methods 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 230000003205 diastolic effect Effects 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 230000035619 diuresis Effects 0.000 description 1
- 239000002934 diuretic Substances 0.000 description 1
- 230000001882 diuretic effect Effects 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 208000001848 dysentery Diseases 0.000 description 1
- 208000010515 dystocia Diseases 0.000 description 1
- 235000005686 eating Nutrition 0.000 description 1
- 235000006694 eating habits Nutrition 0.000 description 1
- IDGUHHHQCWSQLU-UHFFFAOYSA-N ethanol;hydrate Chemical compound O.CCO IDGUHHHQCWSQLU-UHFFFAOYSA-N 0.000 description 1
- YGHHWSRCTPQFFC-UHFFFAOYSA-N eucalyptosin A Natural products OC1C(O)C(O)C(CO)OC1OC1C(OC(C#N)C=2C=CC=CC=2)OC(CO)C(O)C1O YGHHWSRCTPQFFC-UHFFFAOYSA-N 0.000 description 1
- 230000005713 exacerbation Effects 0.000 description 1
- 230000007717 exclusion Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 229930003935 flavonoid Natural products 0.000 description 1
- 150000002215 flavonoids Chemical class 0.000 description 1
- 235000017173 flavonoids Nutrition 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 210000000232 gallbladder Anatomy 0.000 description 1
- 235000008434 ginseng Nutrition 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 238000005469 granulation Methods 0.000 description 1
- 230000003179 granulation Effects 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 208000019622 heart disease Diseases 0.000 description 1
- 230000001146 hypoxic effect Effects 0.000 description 1
- 238000003384 imaging method Methods 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000010354 integration Effects 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 208000028867 ischemia Diseases 0.000 description 1
- 230000000302 ischemic effect Effects 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 210000002429 large intestine Anatomy 0.000 description 1
- 230000003908 liver function Effects 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000002175 menstrual effect Effects 0.000 description 1
- 230000004089 microcirculation Effects 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 230000002107 myocardial effect Effects 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 231100000956 nontoxicity Toxicity 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 231100000614 poison Toxicity 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 208000023482 precordial pain Diseases 0.000 description 1
- 208000020016 psychiatric disease Diseases 0.000 description 1
- 238000010298 pulverizing process Methods 0.000 description 1
- 238000010791 quenching Methods 0.000 description 1
- 230000000171 quenching effect Effects 0.000 description 1
- 239000008517 radix Trichosanthis Substances 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000002040 relaxant effect Effects 0.000 description 1
- 230000008085 renal dysfunction Effects 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 208000026451 salivation Diseases 0.000 description 1
- 201000010153 skin papilloma Diseases 0.000 description 1
- 235000014347 soups Nutrition 0.000 description 1
- 208000005801 spondylosis Diseases 0.000 description 1
- 238000005728 strengthening Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 238000012353 t test Methods 0.000 description 1
- 230000017423 tissue regeneration Effects 0.000 description 1
- 230000001256 tonic effect Effects 0.000 description 1
- 239000003440 toxic substance Substances 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 235000013619 trace mineral Nutrition 0.000 description 1
- 239000011573 trace mineral Substances 0.000 description 1
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 1
- 150000003648 triterpenes Chemical class 0.000 description 1
- 206010047302 ventricular tachycardia Diseases 0.000 description 1
- 239000000341 volatile oil Substances 0.000 description 1
- 230000008673 vomiting Effects 0.000 description 1
- 238000010792 warming Methods 0.000 description 1
- 229940126673 western medicines Drugs 0.000 description 1
- 230000002087 whitening effect Effects 0.000 description 1
Landscapes
- Medicines Containing Plant Substances (AREA)
Abstract
The invention discloses a traditional Chinese medicine composition for treating coronary heart disease and angina pectoris with turbid phlegm and blood stasis and a preparation method thereof, wherein the traditional Chinese medicine composition comprises the following raw materials in parts by weight: 5-35 parts of full trichosanthes kirilowii maxim, 5-25 parts of allium macrostemon, 5-25 parts of pinellia ternate, 5-25 parts of immature bitter orange, 5-25 parts of radix salviae miltiorrhizae, 3-25 parts of ligusticum wallichii, 5-25 parts of radix puerariae, 5-25 parts of radix paeoniae rubra, 3-20 parts of rhizoma corydalis, 3-25 parts of radix curcumae and 3-25 parts of safflower, and preferably at least one of the following raw materials is included: 5-25 parts of raw hawthorn, 3-20 parts of frankincense, 5-25 parts of peach kernel, 15-45 parts of coix seed, 5-25 parts of poria cocos, and 1-15 parts of liquorice. The traditional Chinese medicine composition has the advantages of low medicine cost, simple preparation process, positive clinical effects on improvement of clinical symptoms of patients and improvement of treatment effects, and great popularization value and application prospect.
Description
Technical Field
The invention relates to the technical field of traditional Chinese medicine compositions, in particular to a traditional Chinese medicine composition for treating coronary heart disease and angina pectoris with turbid phlegm and blood stasis symptoms, and a preparation method and application thereof.
Background
Coronary heart disease and angina pectoris are syndrome characterized by precordial pain, and due to coronary stenosis and insufficient blood supply, the heart is transiently ischemic and hypoxic, and chest pain, palpitation and angina pectoris are characterized by, and most angina pectoris is clinically. In recent years, with the continuous improvement of social and economic levels, the incidence rate of coronary heart disease in China is obviously increased. Especially, due to the increase of the aged population, the coronary heart disease tends to increase year by year, and the incidence of coronary heart disease and angina pectoris also increases.
In recent years, due to the improvement of human living standard, eating habits, eating structures and the like are greatly changed, coronary heart disease angina with turbid phlegm and blood stasis is more clinically at present, and main symptoms comprise chest distress and suffocation, or stuffiness pain, stinging pain, no pain, aggravation in overcast and rainy days, fat tongue with tooth marks, ecchymosis, greasy coating and the like; secondary symptoms include gastric and abdominal distress, anorexia, thirst, constipation, nausea, emesis, heavy limbs, dizziness, turbid urine, wiry and thready pulse, etc., which seriously threaten human health. The treatment of coronary heart disease and angina pectoris with turbid phlegm and blood stasis becomes a hot spot problem in the medical field, and the combination of the traditional Chinese medicine and the western medicine in clinic becomes one of popular treatment modes at present. But the effects are all unsatisfactory, and the defects of single target point, large adverse reaction, high treatment cost and the like are all possessed.
The invention patent CN109925399B discloses a compound traditional Chinese medicine composition for treating coronary heart disease, which is mainly prepared from the following raw materials, by weight, 5-10 parts of sun-dried ginseng, 15-30 parts of raw pseudo-ginseng, 10-30 parts of ligusticum wallichii, 15-30 parts of safflower, 8-15 parts of red sage root, 8-15 parts of rhizoma alismatis, 3-8 parts of honey-fried licorice root, 4-10 parts of acanthopanax root, 3-5 parts of astragalus root, 3-5 parts of spatholobus stem, 3-5 parts of tuber fleeceflower stem and 3-5 parts of rhodiola rosea. However, the cost of the medicine adopted by the compound traditional Chinese medicine composition is relatively high, particularly, the preparation process with complex flow, long time consumption and high cost is adopted, the utilization rate of medicinal materials is poor, and a large amount of byproducts are produced in the preparation process.
The invention patent CN115252691B discloses a traditional Chinese medicine composition for treating qi stagnation and blood stasis type coronary heart disease angina, which comprises the following raw materials in parts by weight: 20-40 parts of red sage root, 20-40 parts of radix codonopsis pilosulae, 10-30 parts of rhizoma corydalis, 5-15 parts of radix bupleuri, 5-15 parts of green tangerine orange peel, 20-40 parts of white peony root, 20-30 parts of red paeony root, 10-30 parts of glossy privet fruit, 10-30 parts of eclipta alba, 5-15 parts of rosewood, 20-40 parts of suberect spatholobus stem, 10-30 parts of poria cocos and 3-8 parts of liquorice. The medicine has good therapeutic effect on chest pain, chest distress, short breath, etc. with stagnation of qi and blood stasis type coronary heart disease and angina pectoris clinical symptoms. However, the coronary heart disease angina pectoris with turbid phlegm and blood stasis and the coronary heart disease angina pectoris with qi stagnation and blood stasis have various differences such as different etiologies, different symptoms and different treatment modes, for example, the coronary heart disease angina pectoris with turbid phlegm and blood stasis is mainly caused by viscera dysfunction, so that in-vivo water metabolism is disturbed, and in-vivo water dampness cannot be normally discharged out of the body, and accumulated in the body is pathogenic. And the angina pectoris is mainly caused by the fact that qi and blood are not normally transported to all parts of the organism due to the fact that qi and blood in the body are not smooth, so that the angina pectoris is caused by the fact that the blood is not smooth. Therefore, when the traditional Chinese medicine composition for treating qi stagnation and blood stasis type coronary heart disease angina is used for treating the coronary heart disease angina with turbid phlegm and blood stasis, the symptoms are insufficient, and the pain is difficult to radically relieve.
Therefore, how to provide a traditional Chinese medicine composition for treating coronary heart disease and angina pectoris with the symptoms of turbid phlegm and blood stasis, which has the advantages of simple preparation process, easily available raw materials, low cost and positive clinical effects on improving clinical symptoms of patients, is a technical problem to be solved by the technicians in the field.
Disclosure of Invention
Aiming at the defects in the prior art, the invention provides a traditional Chinese medicine composition for treating coronary heart disease and angina pectoris with turbid phlegm and blood stasis, a preparation method and application thereof, and the traditional Chinese medicine composition with good clinical effect and popularization and application value can be obtained by carefully selecting traditional Chinese medicine raw materials for reasonable proportioning and simply preparing according to the symptoms and clinical response of the coronary heart disease and angina with turbid phlegm and blood stasis.
In a first aspect, the invention provides a traditional Chinese medicine composition for treating coronary heart disease and angina pectoris with turbid phlegm and blood stasis, which comprises the following raw materials in parts by weight:
5-35 parts of full trichosanthes kirilowii maxim, 5-25 parts of allium macrostemon, 5-25 parts of pinellia ternate, 5-25 parts of immature bitter orange, 5-25 parts of radix salviae miltiorrhizae, 3-25 parts of ligusticum wallichii, 5-25 parts of radix puerariae, 5-25 parts of radix paeoniae rubra, 3-20 parts of rhizoma corydalis, 3-25 parts of radix curcumae and 3-25 parts of safflower.
Preferably, the traditional Chinese medicine composition further comprises at least one of the following raw materials in parts by weight: 5-25 parts of raw hawthorn, 3-20 parts of frankincense, 5-25 parts of peach kernel, 15-45 parts of coix seed, 5-25 parts of poria cocos, and 1-15 parts of liquorice. Based on the main raw materials, the invention further provides compatibility of the raw materials according to the summary of clinical practice experience and treatment effect, and comprehensively improves the clinical medication effect of the traditional Chinese medicine composition.
Preferably, the traditional Chinese medicine composition comprises the following raw materials in parts by weight: 10-30 parts of full trichosanthes kirilowii maxim, 10-20 parts of allium macrostemon, 5-20 parts of pinellia ternate, 5-20 parts of immature bitter orange, 10-25 parts of radix salviae miltiorrhizae, 5-20 parts of ligusticum wallichii, 8-20 parts of radix puerariae, 8-20 parts of radix paeoniae rubra, 5-15 parts of rhizoma corydalis, 5-20 parts of radix curcumae, 5-20 parts of safflower, 8-20 parts of raw hawthorn and 5-15 parts of frankincense.
Specifically, the traditional Chinese medicine composition comprises the following raw materials in parts by weight: 20 parts of full trichosanthes kirilowii maxim, 12 parts of allium macrostemon, 10 parts of pinellia ternate, 10 parts of immature bitter orange, 15 parts of red sage root, 10 parts of ligusticum wallichii, 15 parts of radix puerariae, 15 parts of radix paeoniae rubra, 8 parts of rhizoma corydalis, 10 parts of radix curcumae, 10 parts of safflower, 15 parts of raw hawthorn and 8 parts of frankincense.
Preferably, the traditional Chinese medicine composition comprises the following raw materials:
10-30 parts of full trichosanthes kirilowii maxim, 10-20 parts of allium macrostemon, 5-20 parts of pinellia ternate, 5-20 parts of immature bitter orange, 10-25 parts of radix salviae miltiorrhizae, 5-20 parts of ligusticum chuanxiong, 8-20 parts of radix puerariae, 8-20 parts of radix paeoniae rubra, 5-15 parts of rhizoma corydalis, 5-20 parts of radix curcumae, 5-20 parts of safflower, 8-20 parts of raw hawthorn, 5-15 parts of frankincense, 10-20 parts of peach kernel, 20-40 parts of coix seed, 10-20 parts of poria cocos and 1-10 parts of liquorice.
Preferably, the traditional Chinese medicine composition comprises the following raw materials in parts by weight:
15-25 parts of full snakegourd fruit, 10-15 parts of allium macrostemon, 5-15 parts of pinellia tuber, 5-15 parts of immature bitter orange, 10-20 parts of red sage root, 5-15 parts of szechuan lovage rhizome, 10-18 parts of kudzuvine root, 10-18 parts of red paeony root, 5-10 parts of rhizoma corydalis, 5-15 parts of turmeric root-tuber, 5-15 parts of safflower, 10-18 parts of raw hawthorn, 5-10 parts of frankincense, 10-15 parts of peach seed, 25-35 parts of coix seed, 10-15 parts of Indian buead and 2-8 parts of liquoric root.
Preferably, the traditional Chinese medicine composition comprises the following raw materials in parts by weight:
20 parts of trichosanthes kirilowii maxim, 12 parts of allium macrostemon, 10 parts of pinellia ternate, 10 parts of immature bitter orange, 15 parts of red sage root, 10 parts of ligusticum wallichii, 15 parts of radix puerariae, 15 parts of radix paeoniae rubra, 8 parts of rhizoma corydalis, 10 parts of radix curcumae, 10 parts of safflower, 15 parts of raw hawthorn, 8 parts of frankincense, 12 parts of peach kernel, 30 parts of coix seed, 12 parts of poria cocos and 5 parts of liquorice.
The above scheme of the invention is a formula adopted in clinical treatment, a large number of follow-up records of the medication effect of patients are used, raw material formulas with obvious effect and economy are screened, the obtained traditional Chinese medicine composition has wide treatment universality, the range of the raw materials also provides a feasible scheme of prescription adjustment, and the invention can be slightly adjusted according to the specific patient condition on the basis of the medication concept.
The beneficial effects of the invention are further described by combining the effects of the main traditional Chinese medicine components:
All snakegourd fruit: sweet and bitter taste, cold nature, lung and stomach, large intestine meridian, phlegm resolving, and stagnation resolving effects, and can be used for treating chest obstruction, and stagnation of qi in the chest.
Allium macrostemon: pungent and bitter taste, warm nature, no toxicity, and has the effects of regulating qi-flowing, relieving chest stuffiness, activating yang and resolving hard mass, and the Chinese medicine is used for treating diseases such as chest distress and stinging, diarrhea, severe after diarrhea, asthma and the like for a long time.
Pinellia ternate: the Chinese medicinal composition has the effects of removing dampness and resolving phlegm, calming the adverse-rising energy, relieving vomiting, relieving stuffiness and resolving masses and the like, has the characteristics of pungent taste, warm nature, spleen, stomach and lung channel, has the effects of drying dampness and resolving phlegm, calming the adverse-rising energy, relieving stuffiness and resolving masses and the like, and has pharmacological activities of relieving cough and asthma, eliminating phlegm, relieving cough and the like, and contains various chemical components such as volatile oils, organic acids, alkaloids, amino acids, flavonoids, saccharides, various trace elements and the like.
Immature bitter orange: bitter, pungent and sour, slightly cold. Enter spleen and stomach meridians. Break qi, remove food retention, resolve phlegm and resolve distension and fullness. Can be used for treating stagnation, distention and pain, diarrhea, constipation, phlegm stagnation, qi stagnation, chest pain, chest stuffiness, and viscera prolapse.
Root of red-rooted salvia: the root is used as a medicine, contains tanshinone, is a tonic and menstruation-promoting agent, has the effects of removing blood stasis, promoting tissue regeneration, promoting blood circulation, regulating menstruation and the like, and is a gynecological essential medicine for mainly treating uterine bleeding, irregular menstruation, blood stasis, abdominal pain, menstrual pain, amenorrhea and temple pain. Has good effect on treating coronary heart disease.
Ligusticum wallichii: pungent in flavor, warm in nature, enter liver and gallbladder meridians. Promoting qi circulation, resolving stagnation, dispelling pathogenic wind, removing dampness, promoting blood circulation, and relieving pain. For headache, dizziness, hypochondriac pain, abdominal pain, cold arthralgia, spasm of tendons, amenorrhea, dystocia, puerperal stasis, block pain, carbuncle, cellulitis and sore. Can be used for treating menoxenia, amenorrhea, dysmenorrhea, abdominal pain, chest and hypochondrium pain, traumatic injury, headache, and rheumatalgia.
Radix Puerariae: sweet and pungent in flavor and cool in nature. Enter spleen, stomach and lung meridians. Relieving muscle and fever, promoting eruption, promoting salivation, quenching thirst, invigorating yang, relieving diarrhea, dredging meridian passage, and relieving alcoholism. Can be used for treating fever and headache due to exogenous pathogenic factor, headache, strong pain of neck and back, thirst, diabetes, measles, dysentery, diarrhea, dizziness and headache, apoplexy hemiplegia, chest pain, and alcoholic injury.
Radix paeoniae rubra: bitter and slightly cold. Enter liver meridian. Has effects of clearing heat, cooling blood, promoting blood circulation, and removing blood stasis. Can be used for treating heat-induced ying blood, toxic heat, speckle, hematemesis, epistaxis, conjunctival congestion, swelling and pain, liver Yu Xie pain, amenorrhea, dysmenorrhea, abdominal pain, traumatic injury, carbuncle, swelling and sore.
Rhizoma corydalis: it is pungent and bitter in flavor and warm in nature, and is good at dispelling bitter and relieving heat and activating meridians of heart, liver and spleen, promoting blood circulation and activating qi, and relieving pain, so it is indicated for pain due to blood stasis and qi stagnation, especially for cold syndrome.
Radix Curcumae: bitter in flavor and cold in nature. It is nontoxic and enters the three meridians of heart, lung and liver. Has effects of promoting blood circulation, relieving pain, activating qi-flowing, resolving stagnation, clearing heart fire, cooling blood, promoting bile flow, and eliminating jaundice. Can be used for treating chest and hypochondrium pain, chest pain, amenorrhea dysmenorrhea, breast pain, fever unconsciousness, epilepsia, hematemesis, epistaxis, jaundice, and dark urine.
Safflower: the flower is pungent in flavor and warm in nature, and is good at activating blood and removing stasis to promote menstruation and relieve menalgia, so it is indicated for all syndromes of blood stasis with strong medicinal efficacy.
Raw hawthorn: acid, sweet, slightly pungent and slightly warm. It enters spleen, stomach and liver meridians. Has effects of resolving food stagnation, invigorating spleen, activating qi-flowing and removing blood stasis, and can be used for treating food stagnation, gastric cavity fullness, diarrhea and abdominal pain, blood stasis amenorrhea, puerperal blood stasis, thoracalgia, hernia, and pain; hyperlipidemia.
Mastic gum: pungent taste; bitter; micro-temperature. Enters the heart, liver and spleen meridians. Activating blood and promoting qi circulation; menstrual flow and pain are relieved; detumescence and granulation promoting. Pain in the main abdomen; rheumatalgia; amenorrhea dysmenorrhea; traumatic injury and blood stasis pain; carbuncle and abscess; acute appendicitis; the sore is not healed. For stagnation of qi and blood, pain in heart and abdomen, carbuncle, sore, swelling and toxicity, traumatic injury, dysmenorrhea, postpartum blood stasis and stinging.
Peach kernel: bitter and sweet taste, mild nature, and the aqueous extract of semen Persicae, amygdalin and fat of semen Persicae can inhibit platelet aggregation.
Semen Coicis: the Chinese medicinal composition has the effects of invigorating spleen, stomach and lung meridian, promoting diuresis, strengthening spleen, relaxing tendons, removing arthralgia, clearing heat, expelling pus, removing toxic substances, and resolving hard mass, and is mainly used for treating edema, beriberi, dribbling urine, diarrhea, rheumatalgia, spasm of tendons and vessels, flat wart and the like. Modern pharmacological researches have shown that the triglyceride component in coix seed has anti-tumor effect, and has the effects of relieving pain and inflammation, reducing blood pressure, improving glycolipid metabolism, regulating intestinal flora, whitening and the like.
Poria cocos: sweet and bland taste, mild nature, and good property, and can treat heart, lung, spleen, kidney meridian, poria mainly contains 2 kinds of triterpenes and polysaccharides, and has diuretic, antiinflammatory and myocardial contractility improving effects.
Licorice root: it has sweet and neutral nature and taste, and can restore heart, lung, spleen and stomach channels, has effects of invigorating spleen and replenishing qi, moistening lung and relieving cough, relieving pain, harmonizing various medicines, and relieving drug property, and can be used for treating spleen and stomach weakness, deficiency of middle-jiao, cough and asthma, carbuncle, toxic swelling, food and drug poisoning.
In a second aspect, the invention provides a preparation method of the traditional Chinese medicine composition for treating coronary heart disease and angina pectoris with turbid blood stasis, which comprises the following steps:
Step one: weighing raw materials according to a formula, cleaning, crushing, and then soaking in water for 1-5h;
Step two: decocting for 2-3 times, adding 5-10 times of water each time, boiling with strong fire for 1-3 hr, boiling with slow fire for 1-3 hr, optionally boiling with slow fire for 0.5-1 hr, mixing decoctions, filtering, and concentrating to obtain decoction.
Preferably, adding 5-10 times of 50-75wt% ethanol into the medicinal residue obtained by filtering in the second step, continuously reflux-extracting for 2-12 hours, filtering, recovering ethanol to obtain clear filtrate, and mixing the clear filtrate and the decoction uniformly. After decoction and water extraction, the effective components in the medicine residues can be further recycled by alcohol extraction of the medicine residues, so that the utilization rate of the medicinal materials and the content of the effective components in the medicine are improved. Optionally, the residue is dried and then extracted with alcohol, so that the effect of alcohol extraction is prevented from being influenced by the reduction of the alcohol concentration.
Preferably, the decoction is prepared into clinically acceptable traditional Chinese medicine composition preparations directly or after pharmaceutically acceptable auxiliary materials are added, wherein the preparations are selected from granules, tablets, capsules, pills, decoction, oral solutions, oral suspensions or oral emulsions.
Preferably, the Chinese medicinal composition is prepared into an oral solution, and the preparation method further comprises the following steps of:
Step three: standing the decoction overnight, filtering the supernatant, adding sucrose, dissolving, mixing, and diluting with water to obtain oral solution;
step four: and (3) filling the oral solution, and sterilizing to obtain the oral solution.
The mass production of oral solutions is more beneficial to the use and transportation of patients, and provides a foundation for the popularization and the use of traditional Chinese medicine composition products.
Preferably, the formulation of the oral solution: 100g of full trichosanthes kirilowii maxim, 60g of allium macrostemon, 50g of pinellia ternate, 50g of immature bitter orange, 75g of red sage root, 50g of ligusticum wallichii, 75g of radix puerariae, 75g of red paeony root, 40g of rhizoma corydalis, 50g of radix curcumae, 50g of safflower, 75g of raw hawthorn, 40g of frankincense, and optional 60g of peach kernel, 150g of coix seed, 60g of poria cocos and 25g of liquorice, and adding 30-70g of sucrose to prepare 1000ml of oral solution. On the basis of the proportion of the raw materials of the traditional Chinese medicine composition, the prescription is obtained according to clinical experiments, and the traditional Chinese medicine composition has good universality and mouthfeel.
In a third aspect, the invention provides an application of the traditional Chinese medicine composition in preparing a medicine for treating coronary heart disease with phlegm turbidity and blood stasis.
The invention has the following beneficial effects:
(1) The traditional Chinese medicine composition disclosed by the invention is a traditional Chinese medicine preparation which is prepared from traditional Chinese medicine raw materials such as fructus trichosanthis, allium macrostemon, pinellia tuber, immature bitter orange, red sage root, ligusticum wallichii, radix puerariae, radix paeoniae rubra, rhizoma corydalis, radix curcumae, safflower and the like, wherein the radix trichosanthis has the effects of clearing heat, resolving phlegm, resolving masses and detumescence; fructus Trichosanthis has effects of activating qi-flowing, relieving chest stuffiness, clearing heat and eliminating phlegm; pinellia ternate has the effects of eliminating dampness and phlegm, and relieving spasm and pain; herba asari has effects of warming channel, dredging collaterals, dispelling cold and relieving pain; radix Puerariae, rhizoma Ligustici Chuanxiong, radix Paeoniae Rubra, etc. can clear heat, resolve phlegm, remove blood stasis, relieve pain, and improve patients' symptoms of angina pectoris. The pharmaceutical composition can be used for preparing Chinese patent medicines with the effects of resolving phlegm, promoting the circulation of blood and relieving pain, and has the effects of improving microcirculation, inhibiting platelet aggregation and activating, so that the clinical symptoms of patients with coronary heart disease and angina (phlegm turbidity and blood stasis syndrome) are effectively improved.
(2) The invention improves the utilization rate of medicinal materials and the content of effective components of the medicaments simply and efficiently through the steps of cleaning, crushing, soaking, repeated decoction and water extraction, optional alcohol extraction of medicinal residues and the like, and obtains the oral solution which is easy to use, transport and store, thereby being beneficial to popularization and use of products.
Detailed Description
In order to better understand the above technical solution, the following will describe the above technical solution in detail with reference to specific embodiments. It will be apparent that the described embodiments are only some, but not all, embodiments of the invention. All other embodiments, which can be made by those skilled in the art based on the embodiments of the invention without making any inventive effort, are intended to be within the scope of the invention.
The terminology used in the embodiments of the invention is for the purpose of describing particular embodiments only and is not intended to be limiting of the invention. As used in this application and the appended claims, the singular forms "a," "an," and "the" are intended to include the plural forms as well, unless the context clearly indicates otherwise, the "plurality" generally includes at least two.
It should also be noted that the terms "comprises," "comprising," or any other variation thereof, are intended to cover a non-exclusive inclusion, such that a product or apparatus that comprises a list of elements does not include only those elements but may include other elements not expressly listed or inherent to such product or apparatus. Without further limitation, an element defined by the phrase "comprising one … …" does not exclude the presence of other like elements in a commodity or device comprising such elements.
A traditional Chinese medicine composition for treating coronary heart disease and angina pectoris with syndrome of phlegm turbidity and blood stasis is prepared by the following method:
Step one: weighing, by weight, 5-35 parts of trichosanthes kirilowii maxim, 5-25 parts of allium macrostemon, 5-25 parts of pinellia ternate, 5-25 parts of immature bitter orange, 5-25 parts of red sage root, 3-25 parts of ligusticum wallichii, 5-25 parts of radix puerariae, 5-25 parts of radix paeoniae rubra, 3-20 parts of rhizoma corydalis, 3-25 parts of radix curcumae and 3-25 parts of safflower;
optionally cleaning and pulverizing fructus crataegi 5-25 parts, olibanum 3-20 parts, semen Persicae 5-25 parts, coicis semen 15-45 parts, poria 5-25 parts, and Glycyrrhrizae radix 1-15 parts, and soaking in water for 1-5 hr; preferably, the raw materials are crushed and sieved by a sieve with 30-80 meshes, and when water is added for soaking, ultrasonic treatment is carried out for at least 30 minutes;
Step two: decocting for 2-3 times, adding 5-10 times of water each time, boiling with strong fire for 1-3 hr, boiling with slow fire for 1-3 hr, optionally boiling with slow fire for 0.5-1 hr, mixing decoctions, filtering, and concentrating to obtain decoction.
And optionally adding 5-10 times of 50-75wt% ethanol into the medicinal residue obtained in the second filtering step, continuously reflux-extracting for 2-12 hours, filtering, recovering ethanol to obtain clear filtrate, mixing the clear filtrate and the decoction uniformly, and concentrating to obtain water decoction.
The decoction can be taken, but more preferably, the decoction is added with pharmaceutically acceptable auxiliary materials to prepare clinically acceptable traditional Chinese medicine composition preparations, wherein the preparations are selected from granules, tablets, capsules, pills, decoction, oral solutions, oral suspensions or oral emulsions.
More preferably, the water decoction is used for preparing oral solution, and the preparation process further comprises the following steps:
step three: standing the decoction overnight, filtering the supernatant, adding appropriate amount of sucrose, dissolving, mixing, and diluting with water to obtain oral solution; optionally, concentrating the decoction filtrate, and standing overnight;
Step four: filling the oral solution, and sterilizing at 100-120deg.C for 20-40min to obtain oral solution product.
In practical application, the invention also provides oral solutions with the following prescriptions:
100g of full trichosanthes kirilowii maxim, 60g of allium macrostemon, 50g of pinellia ternate, 50g of immature bitter orange, 75g of red sage root, 50g of ligusticum wallichii, 75g of radix puerariae, 75g of red paeony root, 40g of rhizoma corydalis, 50g of radix curcumae, 50g of safflower, 75g of raw hawthorn and 40g of frankincense, and 30-70g of sucrose are added to prepare 1000ml of oral solution. The oral solution has good taste, and is easy to be accepted by patients for long-term administration. 60g of peach kernel, 150g of coix seed, 60g of poria cocos, and 25g of liquorice are added according to the requirements.
Example 1
Sample 1 of this example is 1000mL oral solution prepared from the traditional Chinese medicine composition for treating coronary heart disease and angina pectoris with turbid phlegm and blood stasis symptoms, and is prepared by the following method:
the traditional Chinese medicine composition comprises the following raw materials in parts by weight:
80g of full trichosanthes kirilowii maxim, 45g of allium macrostemon, 40g of pinellia ternate, 40g of immature bitter orange, 50g of red sage root, 40g of ligusticum wallichii, 50g of radix puerariae, 50g of red paeony root, 30g of rhizoma corydalis, 40g of radix curcumae and 40g of safflower;
Step one: weighing the traditional Chinese medicine raw materials according to the above dosage, cleaning, crushing, sieving with a 60-mesh sieve, soaking in water for 3h (wherein ultrasonic treatment is added in the first 30 minutes);
step two: decocting for 2 times, adding 10 times of water for the first time, boiling with strong fire for 1.5h, adding 8 times of water for the second time, adding water for boiling with slow fire for 1.5h, mixing, filtering to obtain decoction, and concentrating to obtain about 800ml water decoction;
step three: standing the decoction overnight, filtering the supernatant, adding 50g sucrose, dissolving, mixing, and diluting with water to 1000mL to obtain oral solution;
step four: filling the oral solution, and sterilizing at 105deg.C for 30min to obtain oral solution.
Example 2
The sample 2 of this example is 1000mL oral solution prepared from the traditional Chinese medicine composition for treating coronary heart disease and angina pectoris with turbid phlegm and blood stasis, and the specific method steps are the same as those of example 1, except that the weight of each component in the traditional Chinese medicine composition is different, and the specific proportion is as follows:
120g of trichosanthes kirilowii maxim, 70g of allium macrostemon, 65g of pinellia ternate, 60g of immature bitter orange, 85g of red sage root, 60g of ligusticum wallichii, 85g of radix puerariae, 85g of red paeony root, 50g of rhizoma corydalis, 65g of radix curcumae and 65g of safflower.
Example 3
Sample 3 of this example is 1000mL oral solution prepared from traditional Chinese medicine composition for treating coronary heart disease and angina pectoris with turbid phlegm and blood stasis, and the specific method steps are the same as those of example 1, except that the weight of each component in the traditional Chinese medicine composition is different, and the specific ratio is as follows:
100g of full trichosanthes kirilowii maxim, 60g of allium macrostemon, 50g of pinellia ternate, 50g of immature bitter orange, 75g of red sage root, 50g of ligusticum wallichii, 75g of radix puerariae, 75g of radix paeoniae rubra, 40g of rhizoma corydalis, 50g of radix curcumae and 50g of safflower.
Example 4
Sample 4 of this example is 1000mL oral solution prepared from traditional Chinese medicine composition for treating coronary heart disease and angina pectoris with turbid phlegm and blood stasis, and the specific method steps are the same as those of example 1, except that the weight of each component in the traditional Chinese medicine composition is different, and the specific ratio is as follows:
100g of full trichosanthes kirilowii maxim, 60g of allium macrostemon, 50g of pinellia ternate, 50g of immature bitter orange, 75g of red sage root, 50g of ligusticum wallichii, 75g of radix puerariae, 75g of red paeony root, 40g of rhizoma corydalis, 50g of radix curcumae, 50g of safflower, 60g of raw hawthorn and 30g of frankincense.
Example 5
The sample 5 of this example is 1000mL oral solution prepared from the traditional Chinese medicine composition for treating coronary heart disease and angina pectoris with turbid phlegm and blood stasis, and the specific method steps are the same as those of example 1, except that the weight of each component in the traditional Chinese medicine composition is different, and the specific proportion is as follows:
100g of full trichosanthes kirilowii maxim, 60g of allium macrostemon, 50g of pinellia ternate, 50g of immature bitter orange, 75g of red sage root, 50g of ligusticum wallichii, 75g of radix puerariae, 75g of red paeony root, 40g of rhizoma corydalis, 50g of radix curcumae, 50g of safflower, 75g of raw hawthorn and 40g of frankincense.
Example 6
Sample 6 of the embodiment is 1000mL oral solution prepared from a traditional Chinese medicine composition for treating coronary heart disease and angina pectoris with turbid phlegm and blood stasis, and the specific method steps are the same as those of embodiment 1, except that the weight of each component in the traditional Chinese medicine composition is different, and the specific proportion is as follows:
100g of full trichosanthes kirilowii maxim, 60g of allium macrostemon, 50g of pinellia ternate, 50g of immature bitter orange, 75g of red sage root, 50g of ligusticum wallichii, 75g of radix puerariae, 75g of red paeony root, 40g of rhizoma corydalis, 50g of radix curcumae, 50g of safflower, 75g of raw hawthorn, 40g of frankincense, 60g of peach kernel, 150g of coix seed, 60g of poria cocos and 25g of liquorice.
Example 7
Sample 7 of this example is a 1000mL oral solution prepared from a traditional Chinese medicine composition for treating coronary heart disease and angina pectoris with turbid phlegm and blood stasis, and the raw materials of the traditional Chinese medicine composition are the same as those of example 6, except that the preparation method is different, and sample 7 is prepared by the following method:
Step one: weighing the traditional Chinese medicine raw materials according to the amount, cleaning, crushing, sieving with a 60-mesh sieve, soaking in water for 3h (wherein ultrasonic treatment is added in the first 30 minutes);
Step two: decocting for 2 times, adding 10 times of water for the first time, boiling with strong fire for 1.5h, adding 8 times of water for the second time, boiling with slow fire for 1.5h, mixing, and filtering to obtain decoction;
Adding 70wt% ethanol water solution with volume of 6 times to the medicinal residue, continuously reflux-extracting for 6 hr, filtering, recovering ethanol to obtain clear filtrate, mixing the clear filtrate with the decoction, and concentrating to obtain water decoction of about 800 ml.
Step three: standing the decoction overnight, filtering the supernatant, adding 50g sucrose, dissolving, mixing, and diluting with water to 1000mL to obtain oral solution;
step four: filling the oral solution, and sterilizing at 105deg.C for 30min to obtain oral solution.
The diagnosis method comprises the following steps:
1. Diagnostic basis
Diagnostic basis of western medicine: refer to "internal science" eighth edition (Ge Junbo), chinese medical society "clinical diagnosis and treatment guide-cardiovascular department division (2009), chinese medical society (2007), and" chronic stable angina pectoris treatment guide (2007).
The Chinese medicine syndrome type: the Chinese medical symptoms are researched according to the clinical research guidelines of treating coronary heart disease by using new Chinese medicines, basic theory of Chinese medicine, diagnosis of Chinese medicine, internal science of Chinese medicine and the like. The clinical study guidelines (2002) of treating coronary heart disease and angina pectoris by using new Chinese medicine are taken as study objects, coronary heart disease (phlegm dampness blood stasis syndrome) is selected as observation index, statistical analysis is carried out on the coronary heart disease by adopting a statistical method, and the action mechanism of the coronary heart disease is discussed.
The main symptoms are as follows: chest choking, or stuffy pain, or stinging pain, or no pain, aggravating in overcast and rainy days, fat tongue with teeth marks, ecchymosis and greasy coating.
Secondary syndrome: gastric and abdominal distress, anorexia, sticky mouth, thirst, constipation, nausea, emesis, heavy limbs, dizziness, turbid urine, and wiry and thready pulse.
There are 3 main symptoms, or 2 main symptoms, with 2 additional symptoms.
2. Inclusion criteria
1) The traditional Chinese medicine clinically has the advantages that the coronary heart disease and the angina pectoris are stable, and more than 2 times of stable myocardial infarction patients exist in a week.
2) Syndrome of turbid phlegm and blood stasis.
3) The electrocardiogram comprises one of the following: (1) Conventional ECG (including conventional ECG performed at the time of acute myocardial infarction) has ischemia (ST segment decrease >0.05mv, or R-wave coupled T-wave amplitude >0.2 mv), (2) electrocardiographic monitoring (ECG). If the conventional ECG has only ST-T type conversion, other coronary artery diseases (such as obvious acute myocardial infarction or coronary angiography, coronary CT or nuclide imaging diagnosis in the past) need to be combined; 2) The secondary electrode electrocardiographic activity plate test is positive.
4) Ages of 35 to 75 years.
5) The subject voluntarily signed his/her before receiving the treatment.
3. Exclusion conditions
1) Diagnosing coronary heart disease acute myocardial infarction or unstable angina pectoris, or staff angina pectoris accompanied with IV-level stability, and chest pain caused by other heart diseases, nerve dysfunction, climacteric syndrome, cervical spondylosis, etc.
2) Poor blood pressure (diastolic or 100 mmHg), severe cardiopulmonary dysfunction, severe arrhythmia (atrial fibrillation, atrial flutter, paroxysmal ventricular tachycardia, type II0 atrioventricular block, bundle branch block).
3) Conventional ECG appears as ST-T changes, but secondary extreme exercise tests are negative, but without other objective evidence, such as coronary angiography or nuclide cardiomyography, without history of stale myocardial infarction, etc.
4) Liver function (ALT, AST) >60U/L, renal dysfunction and mental disorder.
5) Pregnant or lactating females.
6) Patients who have undergone surgical treatment and who have had a potential for bleeding within the last 4 weeks.
7) People who participated in other studies in the last month.
4. Specific clinical diagnostic method
1) 90 Patients with coronary heart disease and angina pectoris with turbid phlegm and blood stasis received by the hospital in the period of 10 months 2020 to 03 months 2023 are selected and classified into an observation group 1 and a control group according to the treatment mode selected by the patients:
observation group 1:60 cases, 34:26 male and female, and the patient age was (49.62.+ -. 8.96) years old;
control group: 30 cases, with a male/female ratio of 17:13 and a patient age of (59.64.+ -. 15.06) years. The patients all meet the requirement of the study, and P is more than 0.05 without statistical significance.
Basic treatment: both groups of patients were routinely given coronary heart disease secondary prevention base drugs (i.e., aspirin, simvastatin, isosorbide dinitrate, etc.) after inclusion.
Observation group 1: the oral solution of sample 5 of example 5 was administered on a basal basis, three times daily, 20ml each time. (the traditional Chinese medicines are provided by the attached Taihe Chinese hospital preparation room of Anhui university of traditional Chinese medicine)
Control group: only basic western medicines are administered for treatment.
2) 120 Patients with coronary heart disease and angina pectoris with turbid phlegm and blood stasis received by the hospital in the period from 2023 month 04 to 2024 month 02 are further selected and classified into an observation group 2 and an observation group 3 according to treatment modes selected by the patients:
observation group 2:60 cases, 34:26 male and female, patient age (50.58 + -9.65) years;
Observation group 3:60 cases, 34:26 male and female, and the patient age was (53.25.+ -. 11.12) years old. The patients all meet the requirement of the study, and P is more than 0.05 without statistical significance.
Basic treatment: both groups of patients were routinely given coronary heart disease secondary prevention base drugs (i.e., aspirin, simvastatin, isosorbide dinitrate, etc.) after inclusion.
Observation group 2: the oral solution of sample 6 of example 6 was administered on a basal basis, three times daily, 20ml each time.
Observation group 3: the oral solution of sample 7 of example 7 was administered on a basal basis, three times daily, 20ml each time. (the traditional Chinese medicines are provided by the attached Taihe Chinese hospital preparation room of Anhui university of traditional Chinese medicine)
The treatment course of the observation groups 1-3 and the control group is 8 weeks.
5. Observation index
The effect of the present study on the total efficacy of the symptoms of the traditional Chinese medicine (determined according to the integration method, efficacy index (n) = (pre-trial integral-post-trial integral)/pre-trial integral x 100%).
Clinical control: n is more than or equal to 90 percent; the effect is shown: 90% n is more than or equal to 70%; progress: n is more than or equal to 30% and less than 70%; invalidation: n < 30%) were compared together.
6. Statistical method
In the study, SPSS25.0 is used as a data statistics analysis tool, the difference between the two groups before and after treatment is compared through t-test, and the significance of the difference between the two groups is clarified, so that effective quantitative interpretation is obtained from a data layer, and the application effect of the trichosanthes kirilowii Maxim soup in the patients is verified.
7. Results
7.1 Comparison of the therapeutic Effect of four groups of patients
The study results show that the treatment effect of the patients in the observation groups 1-3 is obviously better than that of the patients in the control group, and the P is less than 0.05, and the results are shown in tables one to three. And the treatment effect of the patients in the observation groups 2 and 3 is further improved compared with that in the observation group 1, particularly the increase of the significant proportion and the decrease of the aggravation proportion are shown in the second table and the third table.
Table 1 comparison of the patient treatment effect with the control group (example/%)
Where the P value represents the probability that the observed statistic or more extreme case occurs based on the null hypothesis.
If P < 0.05, the result is considered statistically significant,
If p > 0.05, the results are considered not statistically significant.
The T value is a value calculated at the time of T-test and is typically used to compare whether there is a significant difference in the mean of one or both samples. The larger the value, the larger the difference and the more likely it is to reject the null hypothesis.
Table II comparison of patient treatment effect of group 2 with control group (example/%)
Table III patient treatment effect of group 3 was observed as compared to control (example/%)
7.2 Comparison of the total efficacy of symptoms in Chinese medicine for four groups of patients
The study results show that after four groups of patients are treated in different modes, the total curative effect of the traditional Chinese medicine symptoms of the observed groups 1-3 of patients is better than that of the control group, and P is less than 0.05, and the four to six of the table are shown. And the total curative effect of the traditional Chinese medicine symptoms of the patients in the observation groups 2 and 3 is further improved compared with that of the traditional Chinese medicine symptoms in the observation group 1, and particularly, the increase of the clinical control proportion and the decrease of the exacerbation proportion are shown in the fifth and sixth tables.
Table IV observes a comparison of the total efficacy of the symptoms in TCM after treatment in group 1 with the control group (example/%)
Table five observations comparison of the total efficacy of the symptoms in TCM after treatment in group 2 with the control group (example/%)
Table six observations comparison of the total efficacy of the symptoms in TCM after treatment in group 3 with the control group (example/%)
While preferred embodiments of the present invention have been described, additional variations and modifications in those embodiments may occur to those skilled in the art once they learn of the basic inventive concepts. It is therefore intended that the invention be construed as including the preferred embodiments and all such alterations and modifications as fall within the scope of the invention. It will be apparent to those skilled in the art that various modifications and variations can be made to the present invention without departing from the spirit or scope of the invention. Thus, if such modifications and variations of the present invention fall within the scope of the present invention and the equivalent techniques thereof, the present invention is also intended to include such modifications and variations.
Claims (11)
1. The traditional Chinese medicine composition for treating coronary heart disease and angina pectoris with the syndrome of turbid phlegm and blood stasis is characterized by comprising the following raw materials in parts by weight:
5-35 parts of full trichosanthes kirilowii maxim, 5-25 parts of allium macrostemon, 5-25 parts of pinellia ternate, 5-25 parts of immature bitter orange, 5-25 parts of radix salviae miltiorrhizae, 3-25 parts of ligusticum wallichii, 5-25 parts of radix puerariae, 5-25 parts of radix paeoniae rubra, 3-20 parts of rhizoma corydalis, 3-25 parts of radix curcumae and 3-25 parts of safflower.
2. The traditional Chinese medicine composition according to claim 1, further comprising at least one of the following raw materials in parts by weight: 5-25 parts of raw hawthorn, 3-20 parts of frankincense, 5-25 parts of peach kernel, 15-45 parts of coix seed, 5-25 parts of poria cocos, and 1-15 parts of liquorice.
3. The traditional Chinese medicine composition according to claim 1 or 2, wherein the traditional Chinese medicine composition comprises the following raw materials in parts by weight:
20 parts of full trichosanthes kirilowii maxim, 12 parts of allium macrostemon, 10 parts of pinellia ternate, 10 parts of immature bitter orange, 15 parts of red sage root, 10 parts of ligusticum wallichii, 15 parts of radix puerariae, 15 parts of radix paeoniae rubra, 8 parts of rhizoma corydalis, 10 parts of radix curcumae, 10 parts of safflower, 15 parts of raw hawthorn and 8 parts of frankincense.
4. The traditional Chinese medicine composition according to claim 1 or 2, wherein the traditional Chinese medicine composition comprises the following raw materials:
10-30 parts of full trichosanthes kirilowii maxim, 10-20 parts of allium macrostemon, 5-20 parts of pinellia ternate, 5-20 parts of immature bitter orange, 10-25 parts of radix salviae miltiorrhizae, 5-20 parts of ligusticum chuanxiong, 8-20 parts of radix puerariae, 8-20 parts of radix paeoniae rubra, 5-15 parts of rhizoma corydalis, 5-20 parts of radix curcumae, 5-20 parts of safflower, 8-20 parts of raw hawthorn, 5-15 parts of frankincense, 10-20 parts of peach kernel, 20-40 parts of coix seed, 10-20 parts of poria cocos and 1-10 parts of liquorice.
5. The traditional Chinese medicine composition according to claim 4, wherein the traditional Chinese medicine composition comprises the following raw materials in parts by weight:
15-25 parts of full snakegourd fruit, 10-15 parts of allium macrostemon, 5-15 parts of pinellia tuber, 5-15 parts of immature bitter orange, 10-20 parts of red sage root, 5-15 parts of szechuan lovage rhizome, 10-18 parts of kudzuvine root, 10-18 parts of red paeony root, 5-10 parts of rhizoma corydalis, 5-15 parts of turmeric root-tuber, 5-15 parts of safflower, 10-18 parts of raw hawthorn, 5-10 parts of frankincense, 10-15 parts of peach seed, 25-35 parts of coix seed, 10-15 parts of Indian buead and 2-8 parts of liquoric root.
6. The traditional Chinese medicine composition according to claim 5, wherein the traditional Chinese medicine composition comprises the following raw materials in parts by weight:
20 parts of trichosanthes kirilowii maxim, 12 parts of allium macrostemon, 10 parts of pinellia ternate, 10 parts of immature bitter orange, 15 parts of red sage root, 10 parts of ligusticum wallichii, 15 parts of radix puerariae, 15 parts of radix paeoniae rubra, 8 parts of rhizoma corydalis, 10 parts of radix curcumae, 10 parts of safflower, 15 parts of raw hawthorn, 8 parts of frankincense, 12 parts of peach kernel, 30 parts of coix seed, 12 parts of poria cocos and 5 parts of liquorice.
7. A method for preparing a traditional Chinese medicine composition for treating coronary heart disease and angina pectoris with turbid blood stasis according to any one of claims 1 to 6, comprising the following steps:
Step one: weighing raw materials according to a formula, cleaning, crushing, and then soaking in water for 1-5h;
Step two: decocting for 2-3 times, adding 5-10 times of water each time, boiling with strong fire for 1-3 hr, boiling with slow fire for 1-3 hr, optionally boiling with slow fire for 0.5-1 hr, mixing decoctions, filtering, and concentrating to obtain decoction.
8. The preparation method of claim 7, wherein the decoction is prepared into clinically acceptable traditional Chinese medicine composition preparations directly or after adding pharmaceutically acceptable auxiliary materials, and the preparations are selected from granules, tablets, capsules, pills, decoction, oral solutions, oral suspensions or oral emulsions.
9. The method of claim 7 or 8, wherein the composition is formulated as an oral solution, further comprising, after step two:
Step three: standing the decoction overnight, filtering the supernatant, adding sucrose, dissolving, mixing, and diluting with water to obtain oral solution;
step four: and (3) filling the oral solution, and sterilizing to obtain the oral solution.
10. The method of claim 9, wherein the oral solution is formulated by: 100g of full trichosanthes kirilowii maxim, 60g of allium macrostemon, 50g of pinellia ternate, 50g of immature bitter orange, 75g of red sage root, 50g of ligusticum wallichii, 75g of radix puerariae, 75g of red paeony root, 40g of rhizoma corydalis, 50g of radix curcumae, 50g of safflower, 75g of raw hawthorn, 40g of frankincense, and optional 60g of peach kernel, 150g of coix seed, 60g of poria cocos and 25g of liquorice, and adding 30-70g of sucrose to prepare 1000ml of oral solution.
11. The use of the Chinese medicinal composition according to any one of claims 1-6 in the preparation of a medicament for treating coronary heart disease with syndrome of turbid phlegm and blood stasis and angina pectoris.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202410584320.XA CN118356470A (en) | 2024-05-11 | 2024-05-11 | Traditional Chinese medicine composition for treating coronary heart disease and angina pectoris with syndrome of turbid phlegm and blood stasis and preparation method thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202410584320.XA CN118356470A (en) | 2024-05-11 | 2024-05-11 | Traditional Chinese medicine composition for treating coronary heart disease and angina pectoris with syndrome of turbid phlegm and blood stasis and preparation method thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN118356470A true CN118356470A (en) | 2024-07-19 |
Family
ID=91876411
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202410584320.XA Pending CN118356470A (en) | 2024-05-11 | 2024-05-11 | Traditional Chinese medicine composition for treating coronary heart disease and angina pectoris with syndrome of turbid phlegm and blood stasis and preparation method thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN118356470A (en) |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102908583A (en) * | 2012-10-19 | 2013-02-06 | 吉林康乃尔药业有限公司 | Traditional Chinese medicine composition for treating chest stuffiness and pains as well as preparation method, quality detection method and application of composition |
| CN105816811A (en) * | 2016-04-30 | 2016-08-03 | 何佑兵 | Traditional Chinese medicine composition for treating angina and preparing method of traditional Chinese medicine composition |
| CN108295177A (en) * | 2018-03-27 | 2018-07-20 | 南阳理工学院 | It is a kind of to be used to treat Chinese medicine composition of coronary disease and angina pectoris and preparation method thereof |
| CN113577225A (en) * | 2021-08-26 | 2021-11-02 | 宋恩著 | Traditional Chinese medicine composition for treating myocardial infarction as well as preparation method and application thereof |
-
2024
- 2024-05-11 CN CN202410584320.XA patent/CN118356470A/en active Pending
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102908583A (en) * | 2012-10-19 | 2013-02-06 | 吉林康乃尔药业有限公司 | Traditional Chinese medicine composition for treating chest stuffiness and pains as well as preparation method, quality detection method and application of composition |
| CN105816811A (en) * | 2016-04-30 | 2016-08-03 | 何佑兵 | Traditional Chinese medicine composition for treating angina and preparing method of traditional Chinese medicine composition |
| CN108295177A (en) * | 2018-03-27 | 2018-07-20 | 南阳理工学院 | It is a kind of to be used to treat Chinese medicine composition of coronary disease and angina pectoris and preparation method thereof |
| CN113577225A (en) * | 2021-08-26 | 2021-11-02 | 宋恩著 | Traditional Chinese medicine composition for treating myocardial infarction as well as preparation method and application thereof |
Non-Patent Citations (1)
| Title |
|---|
| 倪代梅;班文明;: "豁痰祛瘀汤治疗非ST段抬高急性冠脉综合征60例疗效观察", 中医药临床杂志, no. 05, 31 October 2008 (2008-10-31), pages 468 - 469 * |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| WO2017005220A1 (en) | Chinese medicine composition for treating arrhythmia and manufacturing method thereof | |
| CN115770279B (en) | Traditional Chinese medicine composition for treating chronic lower limb vein diseases, decoction and preparation thereof | |
| CN108310199A (en) | A kind of Chinese medicine composition and its preparation for treating coronary disease and angina pectoris | |
| CN104873705A (en) | Medicinal composition for treating angina pectoris of coronary heart disease and application thereof | |
| CN104857154A (en) | Traditional Chinese medicine composition for treating three-high diseases and preparation method therefor | |
| CN115252753A (en) | Traditional Chinese medicine composition for treating insomnia and application thereof | |
| CN1173726C (en) | Medicine for curing malignant turnor and its preparation method | |
| CN112138084B (en) | Traditional Chinese medicine composition for treating bronchiectasis qi-yin deficiency and phlegm-heat obstructing lung and application thereof | |
| CN118356470A (en) | Traditional Chinese medicine composition for treating coronary heart disease and angina pectoris with syndrome of turbid phlegm and blood stasis and preparation method thereof | |
| CN102204956B (en) | Chinese medicinal composition used at stroke recovery period and preparation method thereof | |
| CN102293985A (en) | Traditional Chinese medicine composition used for treating coronary heart disease and preparation method thereof | |
| CN106620253B (en) | Traditional Chinese medicine composition for treating bradyarrhythmia | |
| CN105233078A (en) | Traditional Chinese medicine composition for treating viral hepatitis | |
| CN112316051A (en) | Traditional Chinese medicine composition for nourishing blood and reducing phlegm as well as traditional Chinese medicine preparation, preparation method and application thereof | |
| CN110882347A (en) | A Chinese medicinal composition for treating cardiovascular diseases | |
| CN105055691A (en) | Traditional Chinese medicine composition efficient in overcoming erectile dysfunction in elderly male | |
| CN112138105B (en) | Traditional Chinese medicine composition for treating bronchiectasis lung-spleen qi deficiency and phlegm-damp lung blocking syndrome and application thereof | |
| CN105477373B (en) | Chinese patent medicine for treating myocardial infarction and preparation method thereof | |
| CN116942771B (en) | Traditional Chinese medicine composition for treating coronary heart disease and application thereof | |
| CN112755137B (en) | Traditional Chinese medicine composition for treating mild and moderate knee osteoarthritis and application thereof | |
| CN114767816B (en) | Traditional Chinese medicine composition for treating coronary heart disease and preparation method thereof | |
| CN115089676B (en) | Application of swertia mileensis-containing traditional Chinese medicine compound composition in preparation of secondary prevention medicine for treating coronary heart disease | |
| CN113144080B (en) | Traditional Chinese medicine for treating coronary atherosclerotic plaques | |
| CN113476526B (en) | A Chinese medicinal composition for treating atrial fibrillation, and its preparation method | |
| CN112826866B (en) | Modified sanguisorba officinalis gargle for treating oral mucositis and preparation method thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination |